[go: up one dir, main page]

DE69931178T8 - Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2 - Google Patents

Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2 Download PDF

Info

Publication number
DE69931178T8
DE69931178T8 DE69931178T DE69931178T DE69931178T8 DE 69931178 T8 DE69931178 T8 DE 69931178T8 DE 69931178 T DE69931178 T DE 69931178T DE 69931178 T DE69931178 T DE 69931178T DE 69931178 T8 DE69931178 T8 DE 69931178T8
Authority
DE
Germany
Prior art keywords
virus
endothelic
vascular
activates
vegf receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE69931178T
Other languages
English (en)
Other versions
DE69931178D1 (de
DE69931178T2 (de
Inventor
M. Lyn WISE
A. Andrew MERCER
J. Loreen SAVORY
B. Stephen FLEMING
Steven A. Angiogenesis Lab. Parkville STACKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
University of Otago
Ludwig Cancer Research
Original Assignee
Ludwig Institute for Cancer Research Ltd
University of Otago
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, University of Otago, Ludwig Cancer Research filed Critical Ludwig Institute for Cancer Research Ltd
Publication of DE69931178D1 publication Critical patent/DE69931178D1/de
Publication of DE69931178T2 publication Critical patent/DE69931178T2/de
Application granted granted Critical
Publication of DE69931178T8 publication Critical patent/DE69931178T8/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69931178T 1998-11-02 1999-11-02 Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2 Active DE69931178T8 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10668998P 1998-11-02 1998-11-02
US106689P 1998-11-02
US10680098P 1998-11-03 1998-11-03
US106800P 1998-11-03
PCT/US1999/025869 WO2000025805A1 (en) 1998-11-02 1999-11-02 Vascular endothelial growth factor-like protein from orf virus nz2 binds and activates mammalian vegf receptor-2

Publications (3)

Publication Number Publication Date
DE69931178D1 DE69931178D1 (de) 2006-06-08
DE69931178T2 DE69931178T2 (de) 2007-02-22
DE69931178T8 true DE69931178T8 (de) 2007-06-28

Family

ID=26803915

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69931178T Active DE69931178T8 (de) 1998-11-02 1999-11-02 Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2

Country Status (8)

Country Link
US (2) US6541008B1 (de)
EP (1) EP1126863B1 (de)
JP (1) JP2003517275A (de)
AT (1) ATE324902T1 (de)
AU (1) AU775956B2 (de)
DE (1) DE69931178T8 (de)
NZ (1) NZ511119A (de)
WO (1) WO2000025805A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
AU2001239884B2 (en) 2000-02-25 2006-08-10 Vegenics Limited Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
CN1455674B (zh) * 2000-07-11 2019-03-29 艾库里斯有限及两合公司 绵羊副痘病毒菌株用于制备抗病毒药物和抗癌药物的用途
DE10122451A1 (de) * 2000-07-11 2002-04-04 Bayer Ag Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2002228841C1 (en) 2000-12-07 2006-11-23 Sangamo Biosciences, Inc Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
ATE359300T1 (de) * 2001-01-19 2007-05-15 Ludwig Inst Cancer Res Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
CN1555488A (zh) * 2001-07-12 2004-12-15 路德维格癌症研究院 淋巴管内皮细胞物质及方法
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
AU2002336866B8 (en) * 2001-11-01 2009-04-23 The University Of British Columbia Diagnosis and treatment of infectious diseases through indel-differentiated proteins
AU2003297282A1 (en) * 2002-11-14 2004-06-15 Cornell Research Foundation, Inc. Protection of cardiac myocardium
EP2351769A3 (de) * 2002-12-17 2011-11-02 AiCuris GmbH & Co. KG Rekombinante Proteine des Parapoxivirus Ovis und pharmazeutische Zusammensetzungen daraus
EP1575614A1 (de) * 2002-12-17 2005-09-21 Bayer HealthCare AG Rekombinante proteine von parapoxvirus ovis und deren pharmazeutische zusammensetzungen
EP1594527A2 (de) * 2003-02-04 2005-11-16 Ludwig Institute For Cancer Research Vegf-b und pdgf modulierung von stammzellen
EP1635860A2 (de) * 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Verwendung von vegf-c oder vegf-d in der wiederherstellende chirurgie
WO2005016963A2 (en) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
CN1934255B (zh) 2003-08-27 2012-07-11 奥普索特克公司 用于治疗眼新血管疾病的组合治疗
JP2005110508A (ja) * 2003-10-02 2005-04-28 Nec Soft Ltd 血管内皮増殖因子受容体２型に対する特異的結合性を有するヘビ毒由来血管内皮増殖因子様タンパク質と用途
WO2005087177A2 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
DE602006020881D1 (de) 2005-08-15 2011-05-05 Vegenics Pty Ltd Enen eigenschaften
AU2013213745B2 (en) * 2005-10-06 2015-10-29 Trophogen, Inc. VEGF analogs and methods of use
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
ES2497641T3 (es) 2006-05-17 2014-09-23 The Ludwig Institute For Cancer Research Dirección a la regulación de VEGF-B de transportadores de ácidos grasos para modular enfermedades humanas
US8741839B2 (en) * 2009-01-18 2014-06-03 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
DK2431168T3 (da) 2010-09-20 2013-07-22 Bekaert Textiles N V Afdækningsmateriale
CA2873881A1 (en) * 2012-05-18 2013-11-21 Stephen Bruce Fleming Combination treatments and compositions for wound healing
US10457713B2 (en) 2012-07-30 2019-10-29 Trophogen, Inc. Glycoprotein hormone long-acting superagonists
EP4012033A1 (de) 2012-07-30 2022-06-15 Trophogen Inc. Langwirkende glykoproteinhormon-superagonisten
JP6408492B2 (ja) 2013-02-18 2018-10-17 ヴェジェニクス プロプライエタリー リミテッドＶｅｇｅｎｉｃｓ Ｐｔｙ Ｌｉｍｉｔｅｄ リガンド結合分子およびその使用
CN105873602A (zh) 2013-11-05 2016-08-17 特洛佛根股份有限公司 糖蛋白激素长效超激动剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
EP0886679B1 (de) * 1996-02-28 2007-06-06 Bayer HealthCare AG Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen
CN1217751A (zh) * 1996-03-29 1999-05-26 奥塔戈大学 副痘病毒载体
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)

Also Published As

Publication number Publication date
ATE324902T1 (de) 2006-06-15
JP2003517275A (ja) 2003-05-27
DE69931178D1 (de) 2006-06-08
NZ511119A (en) 2004-04-30
AU775956B2 (en) 2004-08-19
EP1126863A4 (de) 2003-01-02
EP1126863A1 (de) 2001-08-29
WO2000025805A8 (en) 2000-08-31
US6541008B1 (en) 2003-04-01
DE69931178T2 (de) 2007-02-22
AU1605300A (en) 2000-05-22
US20030211101A1 (en) 2003-11-13
EP1126863B1 (de) 2006-05-03
WO2000025805A1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
DE69931178T8 (de) Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2
CY1119512T1 (el) Αντισωματα του υποδοχεα 1 της ιντερφερονης αλφα και οι χρησεις αυτων
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
DK1325130T3 (da) Nogo-Receptorhomologer
DK0817648T3 (da) Antagonister mod vaskulære endotelcellevækstfaktorer
CY1107475T1 (el) Αναστολεις ρο-κινασης
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
ATE407697T1 (de) Erythropoietin immunglobulin fusionsproteine
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE363531T1 (de) Claudin polypeptide
MXPA05009743A (es) Composiciones con actividad hematopoyetica e inmune.
EP2287194A3 (de) Ephb4-bindende Antikörper zur Inhibierung von Angiogenese und Tumorwachstum
MX2021015651A (es) Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
NO20026286D0 (no) Nye peptider
ATE492266T1 (de) Farbverändernde mittel mit moringa extrakt
DK1301637T3 (da) DNA-vacciner, der koder for HIV accessoriske proteiner
DE60119347D1 (de) Verwendung von chimäres il6-il6r in huntingtonskrankheit
WO2002064621A3 (en) Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent
DE50014789D1 (de) Kombination von verbindungen, welche die biologischen wirkungen von tnf-alpha und cd95l hemmen, in einem arzneimittel
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
MX2023014037A (es) Proteinas de fusion activas renales y metodos de tratamiento que usan las mismas.
ATE492564T1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
CO2023015999A2 (es) Proteínas de fusión activas renales y métodos de tratamiento que usan las mismas
NO982151D0 (no) Hemoregulatoriske forbindelser
ATE382342T1 (de) Pomolsäure zur behandlung von mehrfachresistenten tumoren

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: WISE, M., LYN, DUNEDIN, NZ

Inventor name: MERCER, A., ANDREW, DUNEDIN, NZ

Inventor name: SAVORY, J., LOREEN, DUNEDIN, NZ

Inventor name: FLEMING, B., STEPHEN, DUNEDIN, NZ

Inventor name: STACKER, STEVEN A., ANGIOGENESIS LAB., PARKVIL, US

8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1126863

Country of ref document: EP

Representative=s name: WINTER, BRANDL, FUERNISS, HUEBNER, ROESS, KAIS, DE